Works matching IS 2160763X AND DT 2016 AND VI 5 AND IP 6
Results: 15
Issue Information.
- Published in:
- Clinical Pharmacology in Drug Development, 2016, v. 5, n. 6, p. 427, doi. 10.1002/cpdd.229
- Publication type:
- Article
Ascending Single-Dose, Double-Blind, Placebo-Controlled Safety Study of Noribogaine in Opioid-Dependent Patients.
- Published in:
- Clinical Pharmacology in Drug Development, 2016, v. 5, n. 6, p. 460, doi. 10.1002/cpdd.254
- By:
- Publication type:
- Article
Impact of Renal Impairment on the Pharmacokinetics of Apremilast and Metabolite M12.
- Published in:
- Clinical Pharmacology in Drug Development, 2016, v. 5, n. 6, p. 469, doi. 10.1002/cpdd.256
- By:
- Publication type:
- Article
The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2016, v. 5, n. 6, p. 480, doi. 10.1002/cpdd.259
- By:
- Publication type:
- Article
Glycemic Effect and Safety of a Systemic, Partial Glucokinase Activator, PF-04937319, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin-A Randomized, Crossover, Active-Controlled Study.
- Published in:
- Clinical Pharmacology in Drug Development, 2016, v. 5, n. 6, p. 517, doi. 10.1002/cpdd.261
- By:
- Publication type:
- Article
Pharmacokinetics and Safety of Defibrotide in Healthy Japanese Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2016, v. 5, n. 6, p. 548, doi. 10.1002/cpdd.262
- By:
- Publication type:
- Article
Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals With Renal Impairment.
- Published in:
- Clinical Pharmacology in Drug Development, 2016, v. 5, n. 6, p. 488, doi. 10.1002/cpdd.263
- By:
- Publication type:
- Article
Electrocardiographic Effects of a Supratherapeutic Dose of Oritavancin.
- Published in:
- Clinical Pharmacology in Drug Development, 2016, v. 5, n. 6, p. 502, doi. 10.1002/cpdd.268
- By:
- Publication type:
- Article
Effect of Cabotegravir on Cardiac Repolarization in Healthy Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2016, v. 5, n. 6, p. 509, doi. 10.1002/cpdd.272
- By:
- Publication type:
- Article
Pharmacokinetics, Pharmacodynamics, and Safety of ASP015K (Peficitinib), a New Janus Kinase Inhibitor, in Healthy Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2016, v. 5, n. 6, p. 435, doi. 10.1002/cpdd.273
- By:
- Publication type:
- Article
Pharmacokinetic and Pharmacodynamic Drug Interaction Study of Piragliatin, a Glucokinase Activator, and Glyburide, a Sulfonylurea, in Type 2 Diabetic Patients.
- Published in:
- Clinical Pharmacology in Drug Development, 2016, v. 5, n. 6, p. 552, doi. 10.1002/cpdd.276
- By:
- Publication type:
- Article
Effect of Pradigastat, a Diacylglycerol Acyltransferase 1 Inhibitor, on the QTcF Interval in Humans.
- Published in:
- Clinical Pharmacology in Drug Development, 2016, v. 5, n. 6, p. 450, doi. 10.1002/cpdd.278
- By:
- Publication type:
- Article
Comparison of Capillary and Venous Drug Concentrations After Administration of a Single Dose of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole.
- Published in:
- Clinical Pharmacology in Drug Development, 2016, v. 5, n. 6, p. 528, doi. 10.1002/cpdd.290
- By:
- Publication type:
- Article
Comparison of Capillary and Venous Plasma Drug Concentrations After Repeated Administration of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole.
- Published in:
- Clinical Pharmacology in Drug Development, 2016, v. 5, n. 6, p. 538, doi. 10.1002/cpdd.291
- By:
- Publication type:
- Article
Clinical Pharmacology in Drug Development: Five Years in the Books.
- Published in:
- 2016
- By:
- Publication type:
- Editorial